Weight-Loss drugs may cause hidden anal issues, new study warns
NCT ID NCT07668765
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 100 people with severe obesity who are starting a GLP-1 drug (like Ozempic or Wegovy) to see if it causes new anal or rectal problems within the first 3 months. Participants will have a check-up before starting the drug and again after 3 months to look for issues like hemorrhoids, anal fissures, or changes in bowel habits. The goal is to better understand these side effects so doctors can help patients manage them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 receptor agonist (a class of diabetes/weight-loss drugs)
What this could lead to
If successful, this could help doctors understand and manage common anorectal side effects like constipation or hemorrhoids in people taking GLP-1 drugs for obesity.
What could go wrong
This is a small, early observational study with no control group. It only looks at short-term effects (3 months) and cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MORBID OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gazi University Faculty of Medicine
Ankara, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••